Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · IEX Real-Time Price · USD
17.78 0.59 (3.43%)
Jan 24, 2022 4:00 PM EST - Market closed
Market Cap2.05B
Revenue (ttm)352.89M
Net Income (ttm)106.45M
Shares Out115.45M
EPS (ttm)0.83
PE Ratio21.42
Forward PE18.38
Dividendn/a
Ex-Dividend Daten/a
Volume675,335
Open17.01
Previous Close17.19
Day's Range16.78 - 17.85
52-Week Range15.83 - 31.18
Beta0.61
AnalystsBuy
Price Target25.50 (+43.4%)
Earnings DateFeb 7, 2022

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cu...

IndustryPharmaceuticals
Founded1998
CEOJoseph Belanoff
Employees236
Stock ExchangeNASDAQ
Ticker SymbolCORT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 25.50, which is an increase of 43.42% from the latest price.

Price Target
$25.50
(43.42% upside)
Analyst Consensus: Buy

News

Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - January 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutics...

10 hours ago - Newsfile Corp

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...

13 hours ago - Newsfile Corp

Corcept Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...

3 days ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT

New York, New York--(Newsfile Corp. - January 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT). Such inve...

5 days ago - Newsfile Corp

Corcept Update

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp...

1 week ago - Newsfile Corp

Wall Street Analysts See a 26% Upside in Corcept (CORT): Can the Stock Really Move This High?

The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

2 weeks ago - Zacks Investment Research

CORT vs. ZTS: Which Stock Is the Better Value Option?

CORT vs. ZTS: Which Stock Is the Better Value Option?

Other symbols:ZTS
2 weeks ago - Zacks Investment Research

2 Under-the-Radar Biotech Picks to Buy For The Long Haul

These quiet biotechs are tightly focused and practically alone in their markets.

Other symbols:CPRX
1 month ago - The Motley Fool

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer

MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat ...

1 month ago - GlobeNewsWire

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholde...

NEW YORK--(BUSINESS WIRE)-- #CORT--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (“Corcept” or the...

1 month ago - Business Wire

Why Corcept Therapeutics Stock Was Up 11.6% Friday

Investors may be looking for a bargain after the company was hit with bad news this week.

1 month ago - The Motley Fool

Why Corcept Therapeutics Tanked by Almost 17% Today

A U.S. attorney is interested in the company for the wrong reasons.

1 month ago - The Motley Fool

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat s...

1 month ago - GlobeNewsWire

Why Is Corcept (CORT) Up 6.6% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss

Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.

2 months ago - Zacks Investment Research

Corcept Therapeutics (CORT) Q3 Earnings Top Estimates

Corcept (CORT) delivered earnings and revenue surprises of 26.32% and -1.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

MENLO PARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...

2 months ago - GlobeNewsWire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on No...

2 months ago - GlobeNewsWire

Corcept Therapeutics (CORT) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Moore Kuehn, PLLC Encourages Investors of Corcept Therapeutics, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - October 4, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Corcept Therapeutics,...

3 months ago - Newsfile Corp

Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology ( ESMO21 )...

4 months ago - Benzinga

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with R...

MENLO PARK, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...

4 months ago - GlobeNewsWire

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Pati...

MENLO PARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta...

4 months ago - GlobeNewsWire

William Guyer to join Corcept as Chief Development Officer

MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metab...

5 months ago - GlobeNewsWire

Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.

5 months ago - Zacks Investment Research